E-viri
Recenzirano
Odprti dostop
-
Sasso, Ferdinando Carlo; Simeon, Vittorio; Galiero, Raffaele; Caturano, Alfredo; De Nicola, Luca; Chiodini, Paolo; Rinaldi, Luca; Salvatore, Teresa; Lettieri, Miriam; Nevola, Riccardo; Sardu, Celestino; Docimo, Giovanni; Loffredo, Giuseppe; Marfella, Raffaele; Adinolfi, Luigi Elio; Minutolo, Roberto; Amelia, U; Acierno, C; Calatola, P; Carbonara, O; Conte, G; Corigliano, G; Corigliano, M; D’Urso, R; De Matteo, A; De Nicola, L; De Rosa, N; Del Vecchio, E; Di Giovanni, G; Gatti, A; Gentile, S; Gesuè, L; Improta, L; LampitellaJr, A; Lampitella, A; Lanzilli, A; Lascar, N; Masi, S; Mattei, P; Mastrilli, V; Memoli, P; Minutolo, R; Nasti, R; Pagano, A; Pentangelo, M; Pisa, E; Rossi, E; Sasso, F C; Sorrentino, S; Torella, R; Troise, R; Trucillo, P; Turco, A A; Turco, S; Zibella, F; Zirpoli, L
Cardiovascular diabetology, 11/2022, Letnik: 21, Številka: 1Journal Article
Abstract Background Nephropathy in Diabetes type 2 (NID-2) study is an open-label cluster randomized clinical trial that demonstrated that multifactorial intensive treatment reduces Major Adverse Cardiac Events (MACEs) and overall mortality versus standard of care in type 2 diabetic subjects with albuminuria and no history of cardiovascular disease. Aim of the present post-hoc analysis of NID- 2 study is to evaluate whether the number of risk factors on target associates with patient outcomes. Methods Intervention phase lasted four years and subsequent follow up for survival lasted 10 years. To the aim of this post-hoc analysis, the whole population has been divided into 3 risk groups: 0–1 risk factor (absent/low); 2–3 risk factors (intermediate); 4 risk factors (high). Primary endpoint was a composite of fatal and non-fatal MACEs, the secondary endpoint was all-cause death at the end of the follow-up phase. Results Absent/low risk group included 166 patients (52.4%), intermediate risk group 128 (40.4%) and high-risk group 23 (7.3%). Cox model showed a significant higher risk of MACE and death in the high-risk group after adjustment for confounding variables, including treatment arm (HR 1.91, 95% CI 1.04–3.52, P = 0.038 and 1.96, 95%CI 1.02–3.8, P = 0,045, respectively, vs absent/low risk group). Conclusions This post-hoc analysis of the NID-2 trial indicates that the increase in the number of risk factors at target correlates with better cardiovascular-free survival in patients with type 2 diabetes at high CV risk. Clinical Trial Registration ClinicalTrials.gov number, NCT00535925. https://clinicaltrials.gov/ct2/show/NCT00535925
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.